Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

REMUS PHARMACEUTICALS LTD.

NSE : NABSE : ISIN CODE : INE0O5T01011Industry : TradingHouse : Private

BSE0.000 (0 %)

PREV CLOSE ( ) NA

OPEN PRICE ( ) 0.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 0

TODAY'S LOW / HIGH ( )0.00 0.00

52 WK LOW / HIGH ( ) 00

NSE

This Company is not listed in NSE

Select year

(Rs.in Million)

Particulars

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Profit Before Tax

114.14

46.13

13.58

10.94

Adjustment

1.70

-0.02

1.42

2.14

Changes In working Capital

-32.74

16.21

17.03

3.00

Cash Flow after changes in Working Capital

83.10

62.32

32.02

16.08

Cash Flow from Operating Activities

53.13

50.38

28.38

13.03

Cash Flow from Investing Activities

-151.92

-45.45

-30.90

-5.59

Cash Flow from Financing Activities

117.69

-1.74

-1.15

0.64

Net Cash Inflow / Outflow

18.90

3.18

-3.68

8.08

Opening Cash & Cash Equivalents

11.49

8.31

11.98

3.90

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

30.38

11.49

8.31

11.98